Recent studies have shown that approximately 74.2% of users report some gastrointestinal symptoms, though it's noteworthy that 47.9% of placebo group participants reported similar issues
Wang C, Qiao Q, Chi W, Chen J, Liu W, Tan D, McKechnie S, Lyu DA, Jiang X-F, Zhou W, Xu N, Zhang Q, Xu Z, Liu X (2020) Quantitative design of bright fluorophores and AIEgens by the accurate prediction of twisted intramolecular charge transfer
This "start low, go slow" approach helps the body adjust and minimizes potential side effects
Instead, it may help your provider understand your metabolic predispositions and tailor treatment selection and dosing strategy more precisely